» Articles » PMID: 38432871

Inflammatory Marker Profiles and In-hospital Neurological Deterioration in Patients with Acute Minor Ischemic Stroke

Overview
Specialties Neurology
Pharmacology
Date 2024 Mar 3
PMID 38432871
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: The aim of the study was to analyze the association between inflammatory marker profiles and in-hospital neurological deterioration (ND) in acute ischemic stroke (AIS) patients.

Methods: Data from patients with minor AIS from the Third China National Stroke Registry were analyzed. Inflammatory cytokine levels within 24 h of admission were measured. The primary outcome was in-hospital ND (an increase in National Institutes of Health Stroke Scale score ≥4 from admission to discharge). Associations were evaluated using odds ratios (ORs) and 95% confidence intervals (CIs) derived from logistic regression models. Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were used to evaluate incremental predictive values.

Results: A total of 4031 patients (1246 women, 30.9%) with a median age of 62 years were included. In-hospital ND occurred in 121 patients (3%). Each standard-deviation increase in interleukin (IL)-6 (OR, 1.17 [95% CI, 1.06-1.31]) and high-sensitivity C-reactive protein (hsCRP) (OR, 1.43 [95% CI, 1.24-1.66]) levels was associated with increased in-hospital ND risk. Incremental predictive values for adding IL-6 (IDI, 0.012; NRI, 0.329) but not hsCRP levels to the conventional risk factors were found.

Conclusion: In minor AIS, hsCRP and IL-6 levels were associated with in-hospital ND, including IL-6 levels in prognostic models improved risk classification.

Citing Articles

Clinical and imaging risk factors for early neurological deterioration and long-term neurological disability in patients with single subcortical small infarction.

Feng X, Taiwakuli M, Du J, Zhu W, Xu S BMC Neurol. 2025; 25(1):66.

PMID: 39955506 PMC: 11829468. DOI: 10.1186/s12883-025-04067-x.


Increased opioid consumption in neoadjuvant immunotherapy plus chemotherapy for patients with non-small-cell lung cancer: A multicenter, prospective cohort study.

Wang K, Er J, Zhang Y, Song C, Yu Y, Gao R CNS Neurosci Ther. 2024; 30(8):e14893.

PMID: 39097916 PMC: 11298197. DOI: 10.1111/cns.14893.


Inflammatory marker profiles and in-hospital neurological deterioration in patients with acute minor ischemic stroke.

Yi L, Li Z, Jiang Y, Jiang Y, Meng X, Li H CNS Neurosci Ther. 2024; 30(3):e14648.

PMID: 38432871 PMC: 10909616. DOI: 10.1111/cns.14648.

References
1.
Papadopoulos A, Palaiopanos K, Bjorkbacka H, Peters A, de Lemos J, Seshadri S . Circulating Interleukin-6 Levels and Incident Ischemic Stroke: A Systematic Review and Meta-analysis of Prospective Studies. Neurology. 2021; 98(10):e1002-e1012. PMC: 8967391. DOI: 10.1212/WNL.0000000000013274. View

2.
Bharosay A, Saxena K, Varma M, Bharosay V, Pandey A . Correlation between proinflammatory serum markers: high sensitivity C-reactive protein, interleukin-6 with disability score in acute ischemic stroke. Indian J Clin Biochem. 2012; 26(3):279-82. PMC: 3162955. DOI: 10.1007/s12291-011-0135-1. View

3.
Hsu C, Cheng C, Tsai Y, Lee J, Yang J, Weng H . Perfusion-diffusion Mismatch Predicts Early Neurological Deterioration in Anterior Circulation Infarction without Thrombolysis. Curr Neurovasc Res. 2015; 12(3):277-82. PMC: 5403961. DOI: 10.2174/1567202612666150605122536. View

4.
Deng Q, Huang S, Li S, Zhai Q, Zhang Q, Wang Z . Inflammatory Factors as Potential Markers of Early Neurological Deterioration in Acute Ischemic Stroke Patients Receiving Endovascular Therapy - The AISRNA Study. J Inflamm Res. 2021; 14:4399-4407. PMC: 8421252. DOI: 10.2147/JIR.S317147. View

5.
Vila N, Castillo J, Davalos A, Chamorro A . Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 2000; 31(10):2325-9. DOI: 10.1161/01.str.31.10.2325. View